Gastroenterologists Want More Evidence on Nonmedical Switching
Although the totality of the evidence is reassuring, the jury is still out on nonmedical switching to biosimilars, according to new study results.
In Europe, Secondary Patents Can't Stop Biosimilars, Study Says
European investigators say their analysis of court cases involving innovator monoclonal antibodies suggests secondary patents have generally failed to stop biosimilar competition.
Patient Awareness of Biosimilars Is Poor in Australia, Study Says
Patients in an Australian clinic were generally open to using biosimilars but knew little about them, according to a recent study.
2 Clarke Drive Cranbury, NJ 08512